OPN1SW and acute lymphoblastic leukemia: In the PLAT-02 Phase I study (NCT02028455), 43 of 45 enrolled patients with R/R BCP-ALL (median age 12.3 years, range 1.3–25.4) (26) were infused with the CAR-T product, 28 (62%) for post-HSCT relapse.